Daclatasvir 2HCl is primarily used in the treatment of chronic hepatitis C virus (HCV) infection. It works as a potent inhibitor of the HCV NS5A protein, which is essential for viral replication and assembly. This medication is often prescribed in combination with other antiviral agents, such as sofosbuvir, to enhance its efficacy and achieve higher cure rates. The combination therapy is particularly effective for patients with HCV genotypes 1 and 3, including those with compensated cirrhosis. By blocking the NS5A protein, it significantly reduces the viral load in the body, helping to prevent liver damage, cirrhosis, and hepatocellular carcinoma. Its use has revolutionized HCV treatment, offering a shorter duration of therapy, fewer side effects, and improved patient outcomes compared to older interferon-based regimens.